{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T22:35:08Z","timestamp":1774737308085,"version":"3.50.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10072-021-05312-0","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T17:03:47Z","timestamp":1620752627000},"page":"4289-4291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["GAD65 autoimmunity after treatment with nivolumab: a multifocal presentation"],"prefix":"10.1007","volume":"42","author":[{"given":"Giorgia Teresa","family":"Maniscalco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Zekeridou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lia","family":"Allegorico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Ranieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Pezzella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi Della","family":"Gatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentino","family":"Manzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7806-3103","authenticated-orcid":false,"given":"Sara","family":"Mariotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"5312_CR1","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","volume":"35","author":"M Sznol","year":"2017","unstructured":"Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebb\u00e9 C, Kirkwood JM, Schachter J, Daniels GA, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, McCaffrey J, Power D, Walker D, Bhore R, Jiang J, Hodi FS, Wolchok JD (2017) Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol 35:3815\u20133822. https:\/\/doi.org\/10.1200\/JCO.2016.72.1167","journal-title":"J Clin Oncol"},{"key":"5312_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","volume":"30","author":"M Touat","year":"2017","unstructured":"Touat M, Talmasov D, Ricard D, Psimaras D (2017) Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol 30:659\u2013668. https:\/\/doi.org\/10.1097\/WCO.0000000000000503","journal-title":"Curr Opin Neurol"},{"key":"5312_CR3","doi-asserted-by":"publisher","first-page":"175628641879986","DOI":"10.1177\/1756286418799864","volume":"11","author":"MC Dalakas","year":"2018","unstructured":"Dalakas MC (2018) Neurological complications of immune checkpoint inhibitors: whathappens when you \u2018take the brakes off\u2019 the immune system. Ther Adv Neurol Disord 11:1756286418799864. https:\/\/doi.org\/10.1177\/1756286418799864","journal-title":"Ther Adv Neurol Disord"},{"key":"5312_CR4","doi-asserted-by":"publisher","first-page":"e2442","DOI":"10.1212\/WNL.0000000000010632","volume":"95","author":"E Sechi","year":"2020","unstructured":"Sechi E, Markovic SN, McKeon A, Dubey D, Liewluck T, Lennon VA, Lopez-Chiriboga AS, Klein CJ, Mauermann M, Pittock SJ, Flanagan EP, Zekeridou A (2020) Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology. 95:e2442\u2013e2452. https:\/\/doi.org\/10.1212\/WNL.0000000000010632","journal-title":"Neurology."},{"key":"5312_CR5","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1093\/brain\/awn183","volume":"131","author":"A Saiz","year":"2008","unstructured":"Saiz A, Blanco Y, Sabater L, Gonz\u00e1lez F, Bataller L, Casamitjana R, Rami\u00f3-Torrent\u00e0 L, Graus F (2008) Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 131:2553\u20132563. https:\/\/doi.org\/10.1093\/brain\/awn183","journal-title":"Brain."},{"key":"5312_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00415-019-09666-6","volume":"267","author":"M Chung","year":"2020","unstructured":"Chung M, Jaffer M, Verma N, Mokhtari S, Ramsakal A, Peguero E (2020) Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (Anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange. J Neurol 267:1023\u20131025. https:\/\/doi.org\/10.1007\/s00415-019-09666-6","journal-title":"J Neurol"},{"key":"5312_CR7","doi-asserted-by":"publisher","first-page":"2548528","DOI":"10.1155\/2018\/2548528","volume":"2018","author":"S Shah","year":"2018","unstructured":"Shah S, Dunn-Pirio A, Luedke M, Morgenlander J, Skeen M, Eckstein C (2018) Nivolumab-Induced Autoimmune Encephalitis in Two Patients with Lung Adenocarcinoma. Case Rep Neurol Med 2018:2548528\u20132548524. https:\/\/doi.org\/10.1155\/2018\/2548528","journal-title":"Case Rep Neurol Med"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05312-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05312-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05312-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T03:39:04Z","timestamp":1631763544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05312-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":7,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5312"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05312-0","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]},"assertion":[{"value":"6 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All co-authors approved the publication and agreed to conditions noted on the authorship agreement form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Giorgia Teresa Maniscalco received personal compensation from Serono, Biogen, Novartis, Roche and TEVA for public speaking and advisory boards. Anastasia Zekeridou has a patent on PDE10A-IgG as a marker of paraneoplastic neurological autoimmunity. Sergio Ferrari received a support for congress attendance by Shire, Euroimmun, and Merck Sara Mariotto received support for attending scientific meetings by Merck and Euroimmun.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}